List of Excipients in Branded Drug FLUOCINOLONE ACETONIDE OIL, 0.01% (EAR DROPS)

Generic Drugs Containing FLUOCINOLONE ACETONIDE OIL, 0.01% (EAR DROPS)

Company	Ingredient	NDC	Excipient
Tasman Pharma Inc	fluocinolone acetonide oil, 0.01% (ear drops)	72641-002	ISOPROPYL ALCOHOL
Tasman Pharma Inc	fluocinolone acetonide oil, 0.01% (ear drops)	72641-002	ISOPROPYL MYRISTATE
Tasman Pharma Inc	fluocinolone acetonide oil, 0.01% (ear drops)	72641-002	LIGHT MINERAL OIL
Tasman Pharma Inc	fluocinolone acetonide oil, 0.01% (ear drops)	72641-002	OLETH-2
Tasman Pharma Inc	fluocinolone acetonide oil, 0.01% (ear drops)	72641-002	PEANUT OIL

What are the Most Frequently-Used Excipients in FLUOCINOLONE ACETONIDE OIL, 0.01% (EAR DROPS)?

# Of NDCs	Excipient
1	ISOPROPYL ALCOHOL
1	ISOPROPYL MYRISTATE
1	LIGHT MINERAL OIL
1	OLETH-2
1	PEANUT OIL

Fluocinolone Acetonide Oil 0.01% Ear Drops: Excipient Strategy, Patent Position, and Commercial Opportunities

Last updated: August 3, 2026

Fluocinolone acetonide oil 0.01% is an anhydrous otic corticosteroid used for chronic eczematous external otitis. The reference product, DermOtic Oil, uses refined peanut oil as its vehicle. The main commercial opportunity is a peanut-free, preservative-free oil formulation with equivalent corticosteroid delivery, improved allergy positioning, and differentiated packaging. The core active-ingredient patent barrier appears limited, while formulation, container-closure, manufacturing, and regulatory execution remain the principal entry barriers.

What is fluocinolone acetonide oil 0.01% used for?

Fluocinolone acetonide oil 0.01% is indicated for the topical treatment of chronic eczematous external otitis in adults and pediatric patients aged 2 years and older. The strength is 0.01%, equivalent to 0.1 mg of fluocinolone acetonide per gram or approximately 0.1 mg/mL where density is close to 1 g/mL.[1]

Attribute	Reference product profile
Active ingredient	Fluocinolone acetonide
Strength	0.01%
Dosage form	Otic oil
Route	Topical administration to the external ear canal
Main indication	Chronic eczematous external otitis
Reference brand	DermOtic Oil
Reference NDA	NDA 021785
Vehicle	Refined peanut oil
Preservative system	Anhydrous oil system; no conventional aqueous preservative system
Typical commercial container	Multidose bottle with dropper assembly

The product is a low-potency topical corticosteroid. Its use is concentrated in dermatology, otolaryngology, primary care, and pediatric ear-disorder treatment.

What excipient is used in DermOtic Oil?

DermOtic Oil uses refined peanut oil as the principal, and publicly identified, inactive ingredient. The formulation is an oil solution rather than an emulsion, suspension, gel, or aqueous ear drop.[1]

The excipient strategy has four functional objectives:

1. Dissolve or uniformly distribute the low-dose corticosteroid.
2. Maintain chemical stability in an anhydrous environment.
3. Provide suitable spreading and retention in the external auditory canal.
4. Deliver a reproducible drop volume through the commercial container.

The use of refined peanut oil creates a product-specific safety and market-positioning issue. The labeling identifies peanut oil and carries a warning for patients with known peanut allergy.[1] That warning provides a direct rationale for a peanut-free reformulation.

What commercial opportunities exist for a peanut-free formulation?

A peanut-free product could compete through safety positioning rather than active-ingredient differentiation. The strongest opportunity is a vehicle substitution that preserves the product's oil-based delivery profile while eliminating peanut-derived material.

Potential vehicles include:

Candidate vehicle	Commercial rationale	Principal development concern
Medium-chain triglycerides	Peanut-free, pharmaceutical-grade, low odor, established topical use	Solubility and sensory properties may differ from the reference
Mineral oil	Low cost, chemically stable, widely used in topical products	Viscosity, drop size, and patient acceptability
Isopropyl myristate blends	Improved spreading and low viscosity	Irritation, migration, and otic tolerability
Squalane	Peanut-free and dermatologically familiar	Cost, oxidation control, and limited otic precedent
Caprylic/capric triglyceride blends	Renewable and cosmetically acceptable	Excipient qualification and formulation consistency
Silicone-based vehicles	Potentially clean sensory profile and water resistance	Regulatory precedent, solubility, and container compatibility

Medium-chain triglycerides are the most commercially practical first-line candidate. They are compatible with anhydrous formulations, can be sourced in pharmaceutical grades, and may support a peanut-free claim. Mineral oil is a cost-focused alternative but may produce a heavier feel and different spreading behavior.

A vehicle substitution must preserve more than assay and appearance. The sponsor must compare solubility, dose uniformity, viscosity, density, drop size, evaporation, sedimentation risk, chemical degradation, and local tolerance.

How should the excipient formulation be designed?

Anhydrous oil solution

The preferred platform is an anhydrous oil solution containing fluocinolone acetonide at 0.01%. The formulation should avoid unnecessary water because water introduces microbial-control requirements and can alter corticosteroid stability and ear-canal tolerability.

A practical development target is:

• Fluocinolone acetonide: 0.01% w/w
• Peanut-free oil vehicle: balance
• No antimicrobial preservative unless required by the final container-closure system
• Antioxidant only if forced by degradation data
• No fragrance, coloring agent, or sensitizing excipient

The formulation should be manufactured under controlled low-moisture conditions. Raw-material water content, peroxide value, acid value, and oxidative stability should be monitored for the selected oil.

Solubilization and uniformity

Fluocinolone acetonide has limited water solubility and is suited to an oil-based delivery approach. The development program should establish whether the candidate vehicle produces a true solution across the proposed storage range. A formulation that appears clear at room temperature but crystallizes under cold or accelerated conditions creates dose-uniformity risk.

Critical studies include:

• Solubility at refrigerated, room, and accelerated conditions
• Polarized-light examination for crystallization
• Assay and related substances
• Viscosity and density
• Drop-weight uniformity
• Shake or resuspension requirements, if the product is not a true solution
• Compatibility with bottle, cap, liner, dropper, and tamper-evident components

Preservative-free positioning

A preservative-free product has a credible commercial advantage in the ear-drop category, particularly for patients with irritated or chronically inflamed external ear canals. An anhydrous formulation can support this positioning because the vehicle is less favorable to microbial growth than an aqueous system.

The claim still requires container-closure and in-use stability data. A multidose bottle may introduce contamination during repeated ear-canal administration. Unit-dose packaging could eliminate some in-use contamination concerns but would raise cost, waste, and usability issues.

What formulation patents protect fluocinolone acetonide oil 0.01%?

The commercial patent position should be separated into four categories:

Patent category	Relevance to this product	Expected risk
Active-ingredient patents	Fluocinolone acetonide itself	Low for an old corticosteroid
Reference-product formulation patents	Peanut-oil composition or specific otic formulation	Requires database verification for enforceable claims
Method-of-use patents	Treatment of eczematous external otitis	Potentially limited by age and indication scope
Packaging and manufacturing patents	Dropper, dose delivery, filling, or container systems	Potentially relevant to differentiated products

Fluocinolone acetonide is an established corticosteroid, and the key commercial protection for the reference product is unlikely to come from a live composition-of-matter patent. The more relevant questions are whether any formulation or method patents remain listed or enforceable, and whether a generic applicant must address them through a Paragraph IV certification.

FDA's Orange Book identifies patents and regulatory exclusivities associated with approved drug products. The Orange Book listing for NDA 021785 should be checked at the time of filing because patent listings and marketing status can change.[2] A sponsor should not assume that the absence of an obvious active-ingredient patent eliminates all litigation risk.

What is the Orange Book and Paragraph IV status of fluocinolone acetonide oil?

An ANDA applicant seeking approval of a generic equivalent to the reference product must address patents listed for the reference drug. The possible certifications are Paragraph I, II, III, or IV under the Hatch-Waxman framework.

For a commercial entrant, the relevant pathway is:

1. Confirm the reference listed drug and dosage-form match.
2. Identify all Orange Book-listed patents for NDA 021785.
3. Determine whether each patent is expired, not yet effective, or subject to a Paragraph IV challenge.
4. Submit the appropriate certification with the ANDA.
5. Assess whether the reference sponsor files suit within the statutory period after receiving notice.

A Paragraph IV challenge could create a 30-month stay if the NDA holder or patent owner brings a qualifying infringement action within the applicable statutory period.[3] If no relevant unexpired patents are listed, the entrant may avoid the principal Hatch-Waxman litigation mechanism, although formulation and regulatory disputes remain possible.

A formulation that replaces refined peanut oil may be easier to defend against a composition claim directed narrowly to peanut oil, but it may also fall outside a simple ANDA sameness strategy. The sponsor must balance freedom to operate against regulatory comparability.

Does a peanut-free vehicle require a new drug application or an ANDA?

The pathway depends on whether the proposed product is pharmaceutically equivalent and therapeutically equivalent to the reference product.

An ANDA is strongest where the proposed product matches the reference product in:

• Active ingredient
• Strength
• Dosage form
• Route of administration
• Conditions of use
• Pharmaceutical equivalence
• Labeling, subject to permitted differences

A vehicle change can complicate the determination of sameness. For a topical otic oil, the sponsor must establish that the new excipient does not materially alter local delivery, safety, or effectiveness. FDA may require product-specific comparative testing, including in vitro performance, physicochemical characterization, and possibly clinical or pharmacodynamic evidence.[4]

A 505(b)(2) application may be more suitable if the vehicle, delivery mechanism, indication, or labeling differs materially from the reference product. It can support a differentiated peanut-free product but generally carries higher development cost and a more extensive clinical and regulatory burden than a conventional ANDA.

What FDA regulatory issues affect a peanut-free otic formulation?

The main FDA issues are local safety, product sameness, microbial quality, and container performance.

Local otic safety

The formulation should be evaluated for:

• Ear-canal irritation
• Sensitization
• Ototoxicity risk if the tympanic membrane is not intact
• Effects on epithelial healing
• Compatibility with common otic conditions
• Pediatric tolerability

The reference labeling includes restrictions and warnings relevant to use in the ear. A reformulated product cannot assume that an excipient with dermatologic precedent is acceptable for otic use.

Excipient qualification

The selected oil should have appropriate compendial or pharmaceutical-grade specifications. The FDA Inactive Ingredient Database can support precedent analysis, but database presence does not eliminate the need to justify concentration, route, dosage form, and patient exposure.[5]

Key specifications include:

• Identity
• Purity
• Residual solvents
• Water content
• Peroxide value
• Heavy metals or elemental impurities
• Microbial limits
• Potential allergens
• Extractables and leachables

Labeling

A peanut-free product could support labeling that removes the peanut-oil warning associated with the reference product, but the claim must be supported by supplier controls and finished-product testing. The sponsor should avoid broad "hypoallergenic" language unless it can support the claim under applicable regulatory standards.

How strong is the patent estate for fluocinolone acetonide ear drops?

The estate is likely moderate to weak for the active ingredient but potentially meaningful at the formulation and delivery-system level.

Estate component	Relative strength	Commercial implication
Fluocinolone acetonide molecule	Low	Old corticosteroid with limited composition-of-matter exclusivity
0.01% strength	Low to moderate	Strength alone generally provides limited protection
Peanut-oil vehicle	Moderate if narrowly claimed and enforceable	Peanut-free alternatives may avoid narrow claims
Otic indication	Low to moderate	Method claims may affect labeled-use strategy
Dropper and dose delivery	Moderate	Packaging design-around is usually possible
Manufacturing process	Low to moderate	Process claims matter if they cover a necessary quality attribute
Peanut-free formulation	Potentially high for a new entrant	New composition can generate independent patent protection

A new sponsor could build a layered estate around a peanut-free formulation. Potential claim categories include:

• Fluocinolone acetonide dissolved in a defined medium-chain triglyceride system
• Specific viscosity and drop-volume ranges
• Oxidative-stability limits
• Unit-dose or metered-dose otic packaging
• Preservative-free multidose delivery
• Treatment methods for patients with peanut allergy or excipient intolerance
• Manufacturing processes that prevent crystallization or degradation

The claims must be drafted around measurable composition and performance parameters. A broad claim covering any peanut-free oil vehicle may face written-description, enablement, obviousness, and prior-art challenges.

What formulation and packaging opportunities can create product differentiation?

Peanut-free replacement

This is the clearest opportunity. It addresses a stated limitation of the reference product and can support physician, pharmacist, and patient differentiation.

Unit-dose packaging

Unit-dose ampoules or blow-fill-seal containers can reduce contamination risk and provide a clear preservative-free message. The tradeoffs are higher packaging cost, more material usage, and less convenient treatment for multi-day therapy.

Metered-dose delivery

A metered pump or calibrated dropper could reduce dose variability. The system must work with a viscous oil and remain compatible with the ear canal and package materials.

Improved drop-size control

Drop size affects administered dose and patient experience. A formulation with controlled viscosity and a validated dropper aperture may improve dose reproducibility without changing the active ingredient.

Pediatric-oriented packaging

A smaller bottle, improved grip, and calibrated dropper could address caregiver use. Child-resistant packaging may be required depending on the final presentation and applicable U.S. packaging rules.

Single-use or tamper-evident presentation

These options can support institutional, pediatric, and specialty-clinic channels. They also create additional package and device regulatory work.

Which companies are challenging or competing with fluocinolone acetonide oil?

Competition comes from three groups:

1. Generic fluocinolone acetonide oil products.
2. Other topical corticosteroid otic products.
3. Nonsteroidal or antimicrobial otic therapies used when the diagnosis differs.

The relevant competitive set includes products containing hydrocortisone, dexamethasone, ciprofloxacin combinations, acetic acid, and other topical agents. These products do not always compete directly because the indication, potency, infection status, and tympanic-membrane condition differ.

A peanut-free fluocinolone product would compete most directly with DermOtic Oil and any therapeutically equivalent generic. It would compete indirectly with corticosteroid ear drops that offer aqueous or suspension-based delivery.

A sponsor should track:

• FDA Drug Shortages and discontinuations
• Orange Book marketing status
• Generic approvals under the same active ingredient and dosage form
• National drug codes and wholesaler availability
• Payer formulary placement
• Retail and specialty-pharmacy pricing
• Clinical guideline use in chronic eczematous otitis externa

What generic launch risks exist?

The principal launch risks are regulatory and commercial rather than molecule-patent driven.

Regulatory risk

A different oil vehicle may trigger additional comparability requirements. Failure to demonstrate equivalent local performance can delay approval or force a 505(b)(2) strategy.

Manufacturing risk

Low-dose corticosteroids require tight content-uniformity control. Oil viscosity and temperature can affect filling accuracy and drop delivery. Crystallization during storage can create a clinically meaningful dose problem.

Supply-chain risk

Pharmaceutical-grade oils may vary in oxidation profile, impurity burden, and supplier availability. Dual sourcing should be established before pivotal stability batches.

Market risk

The product treats a relatively narrow indication. Price competition can be severe if multiple ANDA products are approved. A higher-priced product requires a clear value proposition, such as peanut-free composition, unit-dose delivery, or improved dose control.

Litigation risk

Potential disputes may involve Orange Book patents, formulation patents, package patents, trade dress, or labeling. A design-around strategy should be completed before ANDA submission.

How does DermOtic Oil compare with a peanut-free generic?

Factor	DermOtic Oil	Peanut-free reformulation
Active ingredient	Fluocinolone acetonide 0.01%	Same
Vehicle	Refined peanut oil	MCT, mineral oil, or other qualified oil
Allergy positioning	Contains peanut-derived excipient	Can target peanut-allergic or peanut-avoidant patients
Regulatory route	Approved reference product	ANDA or 505(b)(2), depending on sameness
Preservative profile	Anhydrous oil	Can remain preservative-free
Differentiation	Established brand and physician familiarity	Excipient safety, packaging, and delivery
Patent opportunity	Existing formulation and packaging rights	New formulation and device claims
Price position	Brand or authorized generic pricing	Generic or specialty-premium pricing

What is the revenue exposure and market size?

Public product-level revenue for fluocinolone acetonide oil 0.01% is generally not reported separately from broader dermatology or otic portfolios. The product has a narrow indication, so its revenue exposure is likely smaller than that of broad-use topical corticosteroids.

Commercial value can still be created through:

• Higher net price for a differentiated peanut-free product
• Preferred formulary placement based on excipient profile
• Specialty-pharmacy distribution
• Pediatric and allergy-focused prescriber targeting
• Licensing of a validated otic oil platform
• Cross-application of the vehicle and packaging technology to other otic corticosteroids

The most attractive asset is likely a platform formulation that can support multiple otic actives rather than a single-product generic.

What licensing opportunities exist?

Licensing opportunities fall into four areas:

Vehicle technology

A company with a validated peanut-free, anhydrous otic vehicle could license the platform to generic manufacturers or specialty dermatology companies.

Packaging technology

A low-dose metered dropper or unit-dose system could be licensed independently, particularly if it provides validated dose uniformity with viscous oils.

Regional commercialization

A product owner could grant territorial rights to regional generic companies with established otic sales channels. Geographic licensing is most relevant in the United States, Canada, Europe, and selected Latin American markets, where excipient labeling and approval standards differ.

Co-development

A specialty pharmaceutical company could partner with a generic manufacturer that has ANDA infrastructure. The specialty partner would contribute formulation differentiation and market access, while the generic company would manage CMC and regulatory execution.

What geographic coverage matters for the product?

U.S. protection and commercialization depend on FDA approval, Orange Book listings, and U.S. patent rights. Other major jurisdictions require separate analysis:

• European Union: national or decentralized approval, with excipient and pediatric requirements under the applicable framework
• Canada: Health Canada review and product monograph requirements
• Japan: PMDA review and local clinical or bridging expectations
• Latin America: country-specific registration and import requirements
• Emerging markets: local reference-product, bioequivalence, and labeling rules

Peanut-oil labeling can create different commercial effects by jurisdiction. A peanut-free product may have greater value in markets with strict allergen-labeling expectations.

Key Takeaways

• Fluocinolone acetonide oil 0.01% is an anhydrous otic corticosteroid for chronic eczematous external otitis.
• DermOtic Oil uses refined peanut oil, creating a direct opportunity for a peanut-free alternative.
• Medium-chain triglycerides are the most practical initial replacement vehicle.
• The formulation should remain anhydrous and preferably preservative-free.
• The principal technical risks are solubility, crystallization, drop-volume consistency, oxidation, and local otic tolerability.
• The active ingredient is old, so the strongest new patent opportunities are formulation, packaging, dose delivery, and manufacturing claims.
• An ANDA is commercially attractive if the vehicle change can meet pharmaceutical-equivalence and local-delivery requirements.
• A 505(b)(2) pathway may be required if the reformulation materially changes the product's formulation or clinical profile.
• The market is narrow and likely price-sensitive. Commercial differentiation must come from excipient safety, packaging, delivery precision, or platform licensing.
• Before launch, the sponsor should confirm the current Orange Book listing, reference-product status, patent claims, and FDA product-specific requirements.

FAQs About Fluocinolone Acetonide Oil 0.01% Ear Drops

Is fluocinolone acetonide oil 0.01% the same as fluocinolone acetonide cream?

No. The active ingredient and strength may be comparable, but the dosage form, vehicle, route, absorption, labeling, and approved indications differ. A cream cannot be substituted for an otic oil without appropriate medical direction.

Why is peanut oil used in fluocinolone acetonide ear drops?

Peanut oil provides an anhydrous vehicle capable of carrying the low-dose corticosteroid and spreading over the external ear canal. Its presence creates a labeling concern for patients with peanut allergy.

Can medium-chain triglyceride oil replace refined peanut oil?

Potentially, but the replacement must be validated for solubility, stability, drop delivery, local tolerance, and regulatory equivalence. A vehicle substitution is not automatically interchangeable.

Is fluocinolone acetonide oil 0.01% an antibiotic?

No. It is a corticosteroid. It treats inflammation and itching associated with chronic eczematous external otitis but does not treat bacterial or fungal ear infections.

Can a new formulation obtain patents if fluocinolone acetonide is old?

Yes. Patent protection may be available for a novel vehicle composition, concentration range, crystallization-control method, metered-dose package, unit-dose presentation, or method of treating a defined patient population, subject to patentability requirements.

References

1. U.S. Food and Drug Administration. (n.d.). DermOtic Oil: Fluocinolone acetonide oil 0.01% prescribing information. DailyMed. https://dailymed.nlm.nih.gov/

2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations. Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/

3. U.S. Congress. (1984). Drug Price Competition and Patent Term Restoration Act, 21 U.S.C. § 355(j).

4. U.S. Food and Drug Administration. (2022). Draft guidance for industry: Ophthalmic drug products, quality considerations. FDA.

5. U.S. Food and Drug Administration. (n.d.). Inactive Ingredient Database. https://www.accessdata.fda.gov/scripts/cder/iig/